US FDA approves Pfizer’s VELSIPITY™ for Ulcerative Colitis in Adults
Pfizer Inc. announced that the FDA has approved VELSIPITYTM (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for individuals
Read MorePfizer Inc. announced that the FDA has approved VELSIPITYTM (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for individuals
Read MoreAccording to a study, US pharmaceutical behemoth Pfizer has had success in late-stage testing for a nasal spray intended to
Read MoreThe profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is
Read MoreNew research being presented at this year’s European Congress on Obesity (ECO) in Maastricht, Netherlands (4-7 May), suggests that adults
Read MoreThe CDC is considering what to tell the public about second booster shots with mRNA vaccinations for COVID-19. The US
Read MoreCOVID-19 vaccines and boosters provide protection against hospitalization after contracting the coronavirus again, according to a new CDC study. Although
Read MoreThe 17 million Americans who received the one-shot Johnson & Johnson COVID-19 vaccine are less protected against serious illness and
Read MoreRecent Food and Drug Administration (FDA) emergency use authorization for two antiviral COVID-19 pills was considered a crucial turning point
Read MoreThe pandemic presented a best-of-times/worst-of-times scenario for medical marketing. The good: A once-in-a-century public health crisis doubled as a crucible
Read More